114085-91-5

Upstream product

• 104436-91-1 t-butyl 4-bromomethyl-3-methoxybenzoate 
• 114085-90-4 6--3-formylindole 

Downstream Products

• 142535-42-0 tert-butyl (E)-4-<<6--3-<2-(ethoxycarbonyl)-1-propenyl>indol-1-yl>methyl>-3-methoxybenzoate 
• 142535-40-8 N-[4-[6-(N-Cyclopentylmethylcarbamoyl)-3-[2-(morpholinocarbonyl)ethyl]indol-1-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide 
• 142535-41-9 N-[4-[6-(N-Cyclopentylmethylcarbamoyl)-3-[2-(pyrrolidinocarbonyl]ethyl]indol-1-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide 
• 142535-43-1 N-[4-[6-(N-Cyclopentylmethylcarbamoyl)-3-[2-(N,N-dimethylcarbamoyl)propyl]indol-1-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide 
• 142535-39-5 N-[4-[6-(N-Cyclopentylmethylcarbamoyl)-3-[2-(N-methylcarbamoyl)ethyl]indol-1-ylmethyl]-3-methoxybenzoyl]-2-methylbenzenesulphonamide 
• 114086-25-8 tert-butyl 4-<<6--3-<2-(ethoxycarbonyl)propyl>indol-1-yl>methyl>-3-methoxybenzoate 
• 114086-27-0 tert-butyl 4-<<6--3-<2-(N,N-dimethylcarbamoyl)propyl>indol-1-yl>methyl>-3-methoxybenzoate 
• 114086-20-3 4-[6-(N-cyclopentylmethylcarbamoyl)-3-[2-(morpholinocarbonyl)ethyl]-indol-1-ylmethyl]-3-methoxybenzoic acid 
• 114086-26-9 tert-butyl 4-<<6--3-(2-carboxypropyl)indol-1-yl>methyl>-3-methoxybenzoate 
• 114086-21-4 4-[6-(N-cyclopentylmethylcarbamoyl)-3-[2-(pyrrolidinocarbonyl)ethyl]indol-1-ylmethyl]-3-methoxybenzoic acid 
• 114085-93-7 tert-butyl 4-<<6--3-<2-(methoxycarbonyl)ethyl>indol-1-yl>methyl>-3-methoxybenzoate 
• 114086-23-6 4-[6-(N-cyclopentylmethylcarbamoyl)-3-[2-(N,N-dimethylcarbamoyl)propyl]-indol-1-ylmethyl]-3-methoxybenzoic acid 
• 114085-89-1 4-<<6--3-<2-(methoxycarbonyl)ethyl>indol-1-yl>methyl>-3-methoxybenzoic acid 
• 114085-88-0 4-<<6--3-<2-(N-methylcarbamoyl)ethyl>indol-1-yl>methyl>-3-methoxybenzoic acid 

Relevant academic research and scientific papers

1,3,6-Trisubstituted indoles as peptidoleukotriene antagonists: Benefits of a second, polar, pyrrole substituent

1,6-Substituted and 3,5-substituted indoles and indazoles containing acylamino and N-arylsulfonyl amide appendages are potent antagonists of the peptidoleukotrienes LTD4 and LTE4. A compound from the 3,5-substituted indole series, N-[4-[[5-[[(cyclopentyloxy)carbonyl]amino]-1-methylindol-3- yl]methyl]-3-methoxybenzoyl]-2-methyl-benzenesulfonamide (ICI 204,219), is undergoing clinical evaluation for asthma. Two new elements of structural diversity were introduced to this series of antagonists. An investigation of pyrrole substituents in the 1,6-substituted indoles demonstrated that substitution at C-2 was detrimental to biological activity, but the incorporation of hydrophilic groups at C-3 was beneficial. The introduction of a propionamide moiety at C-3 enhanced activity by 1 order of magnitude; N- [4-[[6-(cyclopentylacetamido)-3-[2-(N-methylcarbamoyl)ethyl]indol-1- yl]methyl]-3-methoxybenzoyl]benzenesulfonamide (15c) has a pK(B) of 10.7 at the LTD4 receptor on guinea pig trachea. Modifications of the acylamino portion of the disubstituted antagonists demonstrated that a transposition of the amide CO and NH atoms was viable. N-Cyclopentylmethyl amides in both the 1,6- and 3,5-disubstituted indole series were 1 order of magnitude less potent than the corresponding cyclopentylacetamides. In both series this potency loss could be regained by the incorporation of a propionamide substituent at either C-3 or N-1, respectively. For example, N-[4-[[6-[N- (cyclopentylmethyl)carbamoyl]-3-[2-(pyrrolidin-1-ylcarbonyl)ethyl]indol-1- yl]methyl]-3-methoxybenzoyl]-2-methylbenzenesulfonamide (39c) has a pK(B) of 9.5.

Heterocyclic carboxamides

This invention provides a series of novel heterocyclic carboxamides of formula I in which the group --Y--Z is selected from --C(Ra)=C, --N=C, and --CH(Ra)--CH and the other radicals have the meanings defined in the following specification. The compoun